The Medical Imaging & Technology Alliance (MITA) announced that Sue Bunning has joined the organization as director of PET industry policy. In this role, Bunning will lead the MITA PET Group and the MITA Molecular Imaging Section.
Sue Bunning
“PET is a tremendously valuable technology that has improved our ability to understand, diagnose, and treat a multitude of diseases, as well as to evaluate and manage patient care,” says Patrick Hope, executive director of MITA. “Sue’s deep understanding of the many applications of this imaging modality, coupled with her background in healthcare policy, will help ensure that MITA communicates its value effectively to lawmakers and regulators.”
Bunning also spoke out about her new role, commenting: “It is an honor to join an organization that is committed to safeguarding physician and patient access to life-saving imaging technologies. I look forward to working alongside my new colleagues at MITA to advocate for policies that promote appropriate use of molecular imaging to improve patient care and health outcomes.”
Prior to joining MITA, Bunning held various roles within the nuclear medicine and PET community, most recently as director of health policy and regulatory affairs for the Society of Nuclear Medicine and Molecular Imaging. Bunning also served as the global vice president of government affairs for Covidien (now Medtronic) and director of government affairs for Tyco, where she worked on international trade, tax, and healthcare issues. Her previous experience includes working for the late Congressman Bill Emerson (R-Mo.) and as a constituent caseworker for the Ohio House of Representatives.
Bunning, a native of Cincinnati, Ohio, holds a B.A. from Ohio State University and an M.A. in international transactions from George Mason University.
